Breakthrough to develop new European HQ for Neogene in Amsterdam

Global life sciences real estate developer Breakthrough Properties said on Monday that it has reached an agreement with Neogene Therapeutics to develop its new European headquarters within the campus of the Amsterdam University Medical Center.

Neogene Therapeutics is a wholly owned subsidiary of global biopharmaceutical company AstraZeneca.
Breakthrough, a joint venture of Tishman Speyer and Bellco Capital formed in 2019, acquired the development site from Amsterdam UMC after a highly competitive bidding process, executed the 100% pre-lease to Neogene, and broke ground on the five-story development in August.  Breakthrough is creating a state-of-the-art biotech research facility that will be fully occupied by Neogene upon its completion in the summer of 2025.  
Kavel F by Breakthrough (Kavel F) is destined to become one of the most sustainable laboratory environments in the world. Designed to BREEAM Outstanding certification standards, the all-electric building will layer sustainable technologies to maintain Net Zero Emissions in the energy performance model and is expected to contribute energy back into the electrical grid under normal operating conditions. Key technologies include geothermal storage for sustainable heating and cooling, highly efficient air treatment, PV panels, and phase shift climate ceilings.  
'Breakthrough is thrilled to support the Neogene team as it aims to bring the potential benefits of T cell receptor therapies to more patients with cancer,' said Breakthrough Properties Chief Executive Officer and co-founder Dan Belldegrun. 'Kavel F is emblematic of Breakthrough Properties’ mission to support cutting edge science by delivering high-quality, sustainable environments.'
'As we continue our efforts to pioneer T cell receptor therapies, we are excited to support our further growth in Amsterdam by developing a state-of-the-art R&D building together with Breakthrough Properties, Amsterdam UMC and the City of Amsterdam,' commented Carsten Linnemann, Ph.D., Chief Executive Officer and co-founder of Neogene Therapeutics.
Breakthrough has retained the Dutch construction firm De Vries en Verburg to serve as general contractor on the project and award-winning architecture design network UNStudio.
Breakthrough currently has more than five million square feet in its under-construction and development pipeline across Europe and the United States.


Latest news

Best read stories